The dark and bright side of atherosclerotic calcification

Atherosclerosis

Volumn 238, Issue 2, 2015, Pages 220-230

  Pugliese, Giuseppe ^a   Iacobini, Carla ^a   Fantauzzi, Claudia Blasetti ^a   Menini, Stefano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Advanced glycation lipoxidation endproducts; Calcification; Inflammation; Osteogenic transdifferentiation; Vascular smooth muscle cells

Indexed keywords

BETA CATENIN; CALCIUM; GALECTIN 3; WNT PROTEIN; ADVANCED GLYCATION END PRODUCT; AUTACOID;

ARTERY CALCIFICATION; ATHEROSCLEROTIC CALCIFICATION; BONE DEVELOPMENT; CALCIUM CELL LEVEL; CELL METABOLISM; CELL TRANSDIFFERENTIATION; ELECTRON BEAM TOMOGRAPHY; GENE EXPRESSION; HUMAN; MACROPHAGE; MOLECULAR IMAGING; MORBIDITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR SMOOTH MUSCLE; ANIMAL; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROGNOSIS;

ANIMALS; ATHEROSCLEROSIS; CALCIUM; CELL TRANSDIFFERENTIATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION MEDIATORS; MUSCLE, SMOOTH, VASCULAR; OSTEOGENESIS; PROGNOSIS; SIGNAL TRANSDUCTION; VASCULAR CALCIFICATION;

EID: 84918784842     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.011     Document Type: Review

References (99)

1. Czermack J. Beschreibung und mikroskopische Untersuchung zweierägyptischer Mumien. Sonder-Berichte Akad. Wiss Wien. 1852, 9:427-469.
2. Murphy W.A., Nedden Dz D., Gostner P., Knapp R., Recheis W., Seidler H. The iceman: discovery and imaging. Radiology 2003, 226:614-629.
3. Virchow R. Cellular pathology. As based upon physiological and pathological histology. Lecture XVI-atheromatous affection of arteries. 1858. Nutr. Rev. 1989, 47:23-25.
4. Demer L.L., Tintut Y. Vascular calcification. Pathobiology of a multifaceted disease. Circulation 2008, 117:2938-2948.
5. Giachelli C.M. Vascular calcification mechanisms. J.Am. Soc. Nephrol. 2004, 15:2959-2964.
6. Detrano R., Guerci A.D., Carr J.J., Bild D.E., Burke G., Folsom A.R., Liu K., Shea S., Szklo M., Bluemke D.A., O'Leary D.H., Tracy R., Watson K., Wong N.D., Kronmal R.A. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N.Engl. J. Med. 2008, 358:1336-1345.
7. Kramer H., Toto R., Peshock R., Cooper R., Victor R. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart Study. J.Am. Soc. Nephrol. 2005, 16:507-513.
8. Taylor A.J., Bindeman J., Feuerstein I., Cao F., Brazaitis M., O'Malley P.G. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. J.Am. Coll. Cardiol. 2005, 46:807-814.
9. Erbel R., Möhlenkamp S., Moebus S., Schmermund A., Lehmann N., Stang A., Dragano N., Grönemeyer D., Seibel R., Kälsch H., Bröcker-Preuss M., Mann K., Siegrist J., Jöckel K.H. Heinz Nixdorf Recall Study Investigative Group. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. J.Am. Coll. Cardiol. 2010, 56:1397-1406.
10. Greenland P., Alpert J.S., Beller G.A., Benjamin E.J., Budoff M.J., Fayad Z.A., Foster E., Hlatky M.A., Hodgson J.M., Kushner F.G., Lauer M.S., Shaw L.J., Smith S.C., Taylor A.J., Weintraub W.S., Wenger N.K., Jacobs A.K., Smith S.C., Anderson J.L., Albert N., Buller C.E., Creager M.A., Ettinger S.M., Guyton R.A., Halperin J.L., Hochman J.S., Kushner F.G., Nishimura R., Ohman E.M., Page R.L., Stevenson W.G., Tarkington L.G., Yancy C.W. American College of Cardiology Foundation; American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J.Am. Coll. Cardiol. 2010, 56:e50-e103.
11. Shanahan C.M. Inflammation ushers in calcification: a cycle of damage and protection?. Circulation 2007, 116:2782-2785.
12. Aikawa E., Nahrendorf M., Figueiredo J.-L., Swirski F.K., Shtatland T., Kohler R.H., Jaffer F.A., Aikawa M., Weissleder R. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging invivo. Circulation 2007, 116:2841-2850.
13. Vengrenyuk Y., Carlier S., Xanthos S., Cardoso L., Ganatos P., Virmani R., Einav S., Gilchrist L., Weinbaum S. Ahypothesis for vulnerable plaque rupture due to stress-induced debonding around cellular microcalcifications in thin fibrous caps. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14678-14683.
14. Otsuka F., Sakakura K., Yahagi K., Joner M., Virmani R. Has our understanding of calcification in human coronary atherosclerosis progressed?. Arterioscler. Thromb. Vasc. Biol. 2014, 34:724-736.
15. Mauriello A., Sangiorgi G.M., Virmani R., Trimarchi S., Holmes D.R., Kolodgie F.D., Piepgras D.G., Piperno G., Liotti D., Narula J., Righini P., Ippoliti A., Spagnoli L.G. Apathobiologic link between risk factors profile and morphological markers of carotid instability. Atherosclerosis 2010, 208:572-580.
16. Hansson G.K., Robertson A.K., Söoderberg-Nauclér C. Inflammation and atherosclerosis. Annu. Rev. Pathol. Mech. Dis. 2006, 1:297-329.
17. Bunting C.H. The formation of true bone with cellular (red) marrow in a sclerotic aorta. J.Exp. Med. 1906, 8:365-376.
18. Soor G.S., Vukin I., Leong S.W., Oreopoulos G., Butany J. Peripheral vascular disease: who gets it and why? A histomorphological analysis of 261 arterial segments from 58 cases. Pathology 2008, 40:385-391.
19. Hunt J.L., Fairman R., Mitchell M.E., Carpenter J.P., Golden M., Khalapyan T., Wolfe M., Neschis D., Milner R., Scoll B., Cusack A., Mohler E.R. Bone formation in carotid plaques: a clinicopathological study. Stroke 2002, 33:1214-1219.
20. Menini S., Iacobini C., Ricci C., Blasetti Fantauzzi C., Salvi L., Pesce C.M., Relucenti M., Familiari G., Taurino M., Pugliese G. The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc. Res. 2013, 100:472-480.
21. Friedrich G.J., Moes N.Y., Mühlberger V.A., Gabl C., Mikuz G., Hausmann D., Fitzgerald P.J., Yock P.G. Detection of intralesional calcium by intracoronary ultrasound depends on the histologic pattern. Am. Heart J. 1994, 128:435-441.
22. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet 2014, 383:705-713.
23. Sangiorgi G., Rumberger J.A., Severson A., Edwards W.D., Gregoire J., Fitzpatrick L.A., Schwartz R.S. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J.Am. Coll. Cardiol. 1998, 31:126-133.
24. Virmani R., Burke A.P., Kolodgie F.D., Farb A. Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque. J.Interv. Cardiol. 2003, 16:267-272.
25. Mauriello A., Servadei F., Zoccai G.B., Giacobbi E., Anemona L., Bonanno E., Casella S. Coronary calcification identifies the vulnerable patient rather than the vulnerable plaque. Atherosclerosis 2013, 229:124-129.
26. Otsuka F., Finn A.V., Virmani R. Do vulnerable and ruptured plaques hide in heavily calcified arteries?. Atherosclerosis 2013, 229:34-37.
27. Ehara S., Kobayashi Y., Yoshiyama M., Shimada K., Shimada Y., Fukuda D., Nakamura Y., Yamashita H., Yamagishi H., Takeuchi K., Naruko T., Haze K., Becker A.E., Yoshikawa J., Ueda M. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation 2004, 110:3424-3429.
28. Kataoka Y., Wolski K., Uno K., Puri R., Tuzcu E.M., Nissen S.E., Nicholls S.J. Spotty calcification as a marker of accelerated progression of coronary atherosclerosis: insights from serial intravascular ultrasound. J.Am. Coll. Cardiol. 2012, 59:1592-1597.
29. Vazquez-Figueroa J.G., Rinehart S., Qian Z., Joshi P.H., Sharma A., Lee J., Anderson H., Murrieta L., Wilmer C., Carlson H., Taylor K., Ballard W., Karmpaliotis D., Kalynych A., Brown C., Voros S. Prospective validation that vulnerable plaque associated with major adverse outcomes have larger plaque volume, less dense calcium, and more non-calcified plaque by quantitative, three-dimensional measurements using intravascular ultrasound with radiofrequency backscatter analysis: results from the ATLANTA I Study. J.Cardiovasc. Transl. Res. 2013, 6:762-771.
30. Pu J., Mintz G.S., Biro S., Lee J.B., Sum S.T., Madden S.P., Burke A.P., Zhang P., He B., Goldstein J.A., Stone G.W., Muller J.E., Virmani R., Maehara A. Insights into echo-attenuated plaques, echolucent plaques, and plaques with spotty calcification: novel findings from comparisons among intravascular ultrasound, near-infrared spectroscopy, and pathological histology in 2,294 human coronary artery segments. J.Am. Coll. Cardiol. 2014, 63:2220-2233.
31. Motoyama S., Kondo T., Sarai M., Sugiura A., Harigaya H., Sato T., Inoue K., Okumura M., Ishii J., Anno H., Virmani R., Ozaki Y., Hishida H., Narula J. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J.Am. Coll. Cardiol. 2007, 50:319-326.
32. Shemesh J., Tenenbaum A., Fisman E.Z., Koren-Morag N., Grossman E. Coronary calcium in patients with and without diabetes: first manifestation of acute or chronic coronary events is characterized by different calcification patterns. Cardiovasc. Diabetol. 2013, 12:161.
33. Criqui M.H., Denenberg J.O., Ix J.H., McClelland R.L., Wassel C.L., Rifkin D.E., Carr J.J., Budoff M.J., Allison M.A. Calcium density of coronary artery plaque and risk of incident cardiovascular events. J.Am. Med. Assoc. 2014, 311:271-278.
34. Voros S., Joshi P., Qian Z., Rinehart S., Vazquez-Figueroa J.G., Anderson H., Elashoff M., Murrieta L., Karmpaliotis D., Kalynych A., Brown C., Schaefer E., Asztalos B. Apoprotein B, small-dense LDL and impaired HDL remodeling is associated with larger plaque burden and more noncalcified plaque as assessed by coronary CT angiography and intravascular ultrasound with radiofrequency backscatter: results from the ATLANTA I study. J.Am. Heart Assoc. 2013, 2:e000344.
35. Houslay E.S., Cowell S.J., Prescott R.J., Reid J., Burton J., Northridge D.B., Boon N.A., Newby D.E. Progressive coronary calcification despite intensive lipid-lowering treatment. Heart 2006, 92:1207-1212. Scottish Aortic Stenosis and Lipid Lowering Therapy, Impact on Regression trial Investigators.
36. Terry J.G., Carr J.J., Kouba E.O., Davis D.H., Menon L., Bender K., Chandler E.T., Morgan T., Crouse J.R. Effect of simvastatin (80mg) on coronary and abdominal aortic arterial calcium (from the coronary artery calcification treatment with zocor [CATZ] study). Am. J. Cardiol. 2007, 99:1714-1717.
37. Nicholls S.J., Tuzcu E.M., Wolski K., Sipahi I., Schoenhagen P., Crowe T., Kapadia S.R., Hazen S.L., Nissen S.E. Coronary artery calcification and changes in atheroma burden in response to established medical therapies. J.Am. Coll. Cardiol. 2007, 49:263-270.
38. Shaalan W.E., Cheng H., Gewertz B., McKinsey J.F., Schwartz L.B., Katz D., Cao D., Desai T., Glagov S., Bassiouny H.S. Degree of carotid plaque calcification in relation to symptomatic outcome and plaque inflammation. J.Vasc. Surg. 2004, 40:262-269.
39. Davaine J.M., Quillard T., Brion R., Lapérine O., Guyomarch B., Merlini T., Chatelais M., Guilbaud F., Brennan M.Á., Charrier C., Heymann D., Gouëffic Y., Heymann M.F. Osteoprotegerin, pericytes and bone-like vascular calcification are associated with carotid plaque stability. PLoS One 2014, 9:e107642.
40. Nandalur K.R., Hardie A.D., Raghavan P., Schipper M.J., Baskurt E., Kramer C.M. Composition of the stable carotid plaque: insights from a multidetector computed tomography study of plaque volume. Stroke 2007, 38:935-940.
41. Crawford H.C., Matrisian L.M., Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression invivo. Cancer Res. 1998, 58:5206-5215.
42. Boskey A.L., Maresca M., Ullrich W., Doty S.B., Butler W.T., Prince C.W. Osteopontin-hydroxyapatite interactions invitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner. 1993, 22:147-159.
43. Bruemmer D., Collins A.R., Noh G., Wang W., Territo M., Arias-Magallona S., Fishbein M.C., Blaschke F., Kintscher U., Graf K., Law R.E., Hsueh W.A. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J.Clin. Invest. 2003, 112:1318-1331.
44. Speer M.Y., McKee M.D., Guldberg R.E., Liaw L., Yang H.Y., Tung E., Karsenty G., Giachelli C.M. Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification invivo. J.Exp. Med. 2002, 196:1047-1055.
45. Shao J.S., Sierra O.L., Cohen R., Mecham R.P., Kovacs A., Wang J., Distelhorst K., Behrmann A., Halstead L.R., Towler D.A. Vascular calcification and aortic fibrosis: a bifunctional role for osteopontin in diabetic arteriosclerosis. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1821-1833.
46. Scatena M., Liaw L., Giachelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2302-2309.
47. Meng X., Zhang K., Li J., Dong M., Yang J., An G., et al. Statins induce the accumulation of regulatory T cells in atherosclerotic plaque. Mol. Med. 2012, 18:598-605.
48. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., Boyce B., Zhao M., Gutierrez G. Stimulation of bone formation invitro and in rodents by statins. Science 1999, 286:1946-1949.
49. Robin N.C., Agoston Z., Biechele T.L., James R.G., Berndt J.D., Moon R.T. Simvastatin promotes adult hippocampal neurogenesis by enhancing Wnt/beta-catenin signaling. Stem Cell Rep. 2013, 2:9-17.
50. Kapustin A.N., Davies J.D., Reynolds J.L., McNair R., Jones G.T., Sidibe A., Schurgers L.J., Skepper J.N., Proudfoot D., Mayr M., Shanahan C.M. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ. Res. 2011, 109:e1-12.
51. New S.E., Goettsch C., Aikawa M., Marchini J.F., Shibasaki M., Yabusaki K., Libby P., Shanahan C.M., Croce K., Aikawa E. Macrophage-derived matrix vesicles: an alternative novel mechanism for microcalcification in atherosclerotic plaques. Circ. Res. 2013, 113:72-77.
52. Speer M.Y., Yang H.Y., Brabb T., Leaf E., Look A., Lin W.L., Frutkin A., Dichek D., Giachelli C.M. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circ. Res. 2009, 104:733-741.
53. Steitz S.A., Speer M.Y., Curinga G., Yang H.Y., Haynes P., Aebersold R., Schinke T., Karsenty G., Giachelli C.M. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ. Res. 2001, 89:1147-1154.
54. Fadini G.P., Albiero M., Menegazzo L., Boscaro E., Vigili de Kreutzenberg S., Agostini C., Cabrelle A., Binotto G., Rattazzi M., Bertacco E., Bertorelle R., Biasini L., Mion M., Plebani M., Ceolotto G., Angelini A., Castellani C., Menegolo M., Grego F., Dimmeler S., Seeger F., Zeiher A., Tiengo A., Avogaro A. Widespread increase in myeloid calcifying cells contributes to ectopic vascular calcification in type 2 diabetes. Circ. Res. 2011, 108:1112-1121.
55. Duffield J.S., Lupher M., Thannickal V.J., Wynn T.A. Host responses in tissue repair and fibrosis. Annu. Rev. Pathol. 2013, 8:241-276.
56. Lech M., Anders H.J. Macrophages and fibrosis: how resident and infiltrating mononuclear phagocytes orchestrate all phases of tissue injury and repair. Biochim. Biophys. Acta 2013, 1832:989-997.
57. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11:723-737.
58. Borthwick L.A., Wynn T.A., Fisher A.J. Cytokine mediated tissue fibrosis. Biochim. Biophys. Acta 2013, 1832:1049-1060.
59. Delaisse J.M. The reversal phase of the bone-remodeling cycle: cellular prerequisites for coupling resorption and formation. Bonekey Rep. 2014, 3:561.
60. Boulter L., Govaere O., Bird T.G., Radulescu S., Ramachandran P., Pellicoro A., Ridgway R.A., Seo S.S., Spee B., Van Rooijen N., Sansom O.J., Iredale J.P., Lowell S., Roskams T., Forbes S.J. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat. Med. 2012, 18:572-579.
61. Demer L., Tintut Y. The roles of lipid oxidation products and receptor activator of nuclear factor-κB signaling in atherosclerotic calcification. Circ. Res. 2011, 108:1482-1493.
62. Liberman M., Bassi E., Martinatti M.K., Lario F.C., Wosniak J., Pomerantzeff P.M., Laurindo F.R. Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler. Thromb. Vasc. Biol. 2008, 28:463-470.
63. Hofmann Bowman M.A., Gawdzik J., Bukhari U., Husain A.N., Toth P.T., Kim G., et al. S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler. Thromb. Vasc. Biol. 2011, 31:337-344.
64. Wang Z., Jiang Y., Liu N., Ren L., Zhu Y., An Y., Chen D. Advanced glycation end-product Nε-carboxymethyl-lysine accelerates progression of atherosclerotic calcification in diabetes. Atherosclerosis 2012, 221:387-396.
65. Cai Z., Li F., Gong W., Liu W., Duan Q., Chen C., Ni L., Xia Y., Cianflone K., Dong N., Wang D.W. Endoplasmic reticulum stress participates in aortic valve calcification in hypercholesterolemic animals. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2345-2354.
66. Derwall M., Malhotra R., Lai C.S., Beppu Y., Aikawa E., Seehra J.S., Zapol W.M., Bloch K.D., Yu P.B. Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012, 32:613-622.
67. Bennett B.J., Scatena M., Kirk E.A., Rattazzi M., Varon R.M., Averill M., Schwartz S.M., Giachelli C.M., Rosenfeld M.E. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2117-2124.
68. Callegari A., Coons M.L., Ricks J.L., Yang H.L., Gross T.S., Huber P., Rosenfeld M.E., Scatena M. Bone marrow- or vessel wall-derived osteoprotegerin is sufficient to reduce atherosclerotic lesion size and vascular calcification. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2491-2500.
69. Osako M.K., Nakagami H., Shimamura M., Koriyama H., Nakagami F., Shimizu H., Miyake T., Yoshizumi M., Rakugi H., Morishita R. Cross-talk of receptor activator of nuclear factor-κB ligand signaling with renin-angiotensin system in vascular calcification. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1287-1296.
70. Osako M.K., Nakagami H., Koibuchi N., Shimizu H., Nakagami F., Koriyama H., Shimamura M., Miyake T., Rakugi H., Morishita R. Estrogen inhibits vascular calcification via vascular RANKL system: common mechanism of osteoporosis and vascular calcification. Circ. Res. 2010, 107:466-475.
71. Hanssen N.M., Wouters K., Huijberts M.S., Gijbels M.J., Sluimer J.C., Scheijen J.L., Heeneman S., Biessen E.A., Daemen M.J., Brownlee M., de Kleijn D.P., Stehouwer C.D., Pasterkamp G., Schalkwijk C.G. Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur. Heart J. 2014, 35:1137-1146.
72. Paloian N.J., Giachelli C.M. Acurrent understanding of vascular calcification in CKD. Am. J. Physiol. Ren. Physiol. 2014 Aug 20, 307:F891-F900.
73. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008, 196:9-21.
74. Iacobini C., Menini S., Ricci C., Scipioni A., Sansoni V., Cordone S., Taurino M., Serino M., Marano G., Federici M., Pricci F., Pugliese G. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler. Thromb. Vasc. Biol. 2009, 29:831-836.
75. MacKinnon A.C., Liu X., Hadoke P.W., Miller M.R., Newby D.E., Sethi T. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology 2013, 23:654-663.
76. Zhu W., Sano H., Nagai R., Fukuhara K., Miyazaki A., Horiuchi S. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem. Biophys. Res. Commun. 2001, 280:1183-1188.
77. Henderson N.C., Sethi T. The regulation of inflammation by galectin-3. Immunol. Rev. 2009, 230:160-171.
78. Shimura T., Takenaka Y., Fukumori T., Tsutsumi S., Okada K., Hogan V., Kikuchi A., Kuwano H., Raz A. Implication of galectin-3 in Wnt signaling. Cancer Res. 2005, 65:3535-3537.
79. Glass D.A., Karsenty G. Invivo analysis of Wnt signaling in bone. Endocrinology 2007, 148:2630-2634.
80. Demetriou M., Granovsky M., Quaggin S., Dennis J.W. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 2001, 409:733-739.
81. MacKinnon A.C., Farnworth S.L., Hodkinson P.S., Henderson N.C., Atkinson K.M., Leffler H., Nilsson U.J., Haslett C., Forbes S.J., Sethi T. Regulation of alternative macrophage activation by galectin-3. J.Immunol. 2008, 180:2650-2658.
82. Li G., Xu J., Li Z. Receptor for advanced glycation end products inhibits proliferation in osteoblast through suppression of Wnt, PI3K and ERK signaling. Biochem. Biophys. Res. Commun. 2012, 423:684-689.
83. Stock M., Schäfer H., Stricker S., Gross G., Mundlos S., Otto F. Expression of galectin-3 in skeletal tissues is controlled by Runx2. J.Biol. Chem. 2003, 278:17360-17367.
84. Colnot C., Sidhu S.S., Poirier F., Balmain N. Cellular and subcellular distribution of galectin-3 in the epiphyseal cartilage and bone of fetal and neonatal mice. Cell. Mol. Biol. 1999, 45:1191-1202.
85. Li Y.-J., Kukita A., Teramachi J., Nagata K., Wu Z., Akamine A., Kukita T. Apossible suppressive role of galectin-3 in upregulated osteoclastogenesis accompanying adjuvant-induced arthritis in rats. Lab. Invest. 2009, 89:26-37.
86. Zhou Z., Immel D., Xi C.X., Bierhaus A., Feng X., Mei L., et al. Regulation of osteoclast function and bone mass by RAGE. J.Exp. Med. 2006, 203:1067-1080.
87. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., Tan H.L., Elliott G., Kelley M.J., Sarosi I., Wang L., Xia X.Z., Elliott R., Chiu L., Black T., Scully S., Capparelli C., Morony S., Shimamoto G., Bass M.B., Boyle W.J. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:3540-3545.
88. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H.L., Xu W., Lacey D.L., Boyle W.J., Simonet W.S. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998, 12:1260-1268.
89. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Lüthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
90. Min H., Morony S., Sarosi I., Dunstan C.R., Capparelli C., Scully S., Van G., Kaufman S., Kostenuik P.J., Lacey D.L., Boyle W.J., Simonet W.S. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J.Exp. Med. 2000, 192:463-474.
91. Persy V., D'Haese P. Vascular calcification and bone disease: the calcification paradox. Trends Mol. Med. 2009, 15:405-416.
92. Kiel D.P., Kauppila L.I., Cupples L.A., Hannan M.T., O'Donnell C.J., Wilson P.W. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif. Tissue Int. 2001, 68:271-276.
93. Panizo S., Cardus A., Encinas M., Parisi E., Valcheva P., López-Ongil S., Coll B., Fernandez E., Valdivielso J.M. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ. Res. 2009, 104:1041-1048.
94. Goettsch C., Iwata H., Aikawa E. Parathyroid hormone: critical bridge between bone metabolism and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2014, 34:1333-1335.
95. Parhami F., Morrow A.D., Balucan J., Leitinger N., Watson A.D., Tintut Y., Berliner J.A., Demer L.L. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler. Thromb. Vasc. Biol. 1997, 17:680-687.
96. Franke S., Rüster C., Pester J., Hofmann G., Oelzner P., Wolf G. Advanced glycation end products affect growth and function of osteoblasts. Clin. Exp. Rheumatol. 2011, 29:650-660.
97. Hamann C., Kirschner S., Günther K.-P., Hofbauer L.C. Bone, sweet bone-osteoporotic fractures in diabetes mellitus. Nat. Rev. Endocrinol. 2012, 8:297-305.
98. Kislinger T., Fu C., Huber B., Qu W., Taguchi A., Du Yan S., et al. N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J.Biol. Chem. 1999, 274:31740-31749.
99. Hutcheson J.D., Maldonado N., Aikawa E. Small entities with large impact: microcalcifications and atherosclerotic plaque vulnerability. Curr. Opin. Lipidol. 2014, 25:327-332.